
1. Malar J. 2016 Jul 7;15(1):347. doi: 10.1186/s12936-016-1379-2.

Prevalence of anti-malarial resistance genes in Dakar, Senegal from 2013 to 2014.

Boussaroque A(1), Fall B(2), Madamet M(3)(4)(5), Wade KA(6), Fall M(7), Nakoulima
A(8), Fall KB(9), Dionne P(10), Benoit N(3)(4)(5), Diatta B(7)(11), Diemé Y(2),
Wade B(11), Pradines B(12)(13)(14)(15).

Author information: 
(1)Unité de Parasitologie et d'Entomologie, Département des Maladies
Infectieuses, Institut de Recherche Biomédicale des Armées, Brétigny Sur Orge,
France.
(2)Laboratoire d'étude de la chimiosensibilité du paludisme, Fédération des
Laboratoires, Hôpital Principal de Dakar, Dakar, Senegal.
(3)Equipe Résidente de Recherche en Infectiologie Tropicale, Institut de
Recherche Biomédicale des Armées, Hôpital d'Instruction des Armées, Marseille,
France.
(4)Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UM 
63, CNRS 7278, IRD 198, Inserm 1095, Aix Marseille Université, Marseille, France.
(5)Centre National de Référence du Paludisme, Marseille, France.
(6)Service des Urgences, Hôpital Principal de Dakar, Dakar, Senegal.
(7)Service de Réanimation Médicale, Hôpital Principal de Dakar, Dakar, Senegal.
(8)Service de Pédiatrie, Hôpital Principal de Dakar, Dakar, Senegal.
(9)Service de Pathologie Infectieuse, Hôpital Principal de Dakar, Dakar, Senegal.
(10)Maternité Hôpital Principal de Dakar, Dakar, Senegal.
(11)Chefferie, Hôpital Principal de Dakar, Dakar, Senegal.
(12)Unité de Parasitologie et d'Entomologie, Département des Maladies
Infectieuses, Institut de Recherche Biomédicale des Armées, Brétigny Sur Orge,
France. bruno.pradines@free.fr.
(13)Laboratoire d'étude de la chimiosensibilité du paludisme, Fédération des
Laboratoires, Hôpital Principal de Dakar, Dakar, Senegal. bruno.pradines@free.fr.
(14)Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes, UM
63, CNRS 7278, IRD 198, Inserm 1095, Aix Marseille Université, Marseille, France.
bruno.pradines@free.fr.
(15)Centre National de Référence du Paludisme, Marseille, France.
bruno.pradines@free.fr.

BACKGROUND: To determine the impact of the introduction of artemisinin-based
combination therapy (ACT) on parasite susceptibility, a molecular surveillance
for antimalarial drug resistance was conducted on local isolates from the Hôpital
Principal de Dakar between November 2013 and January 2014 and between August 2014
and December 2014.
METHODS: The prevalence of genetic polymorphisms in antimalarial resistance genes
(pfcrt, pfmdr1, pfdhfr and pfdhps) was evaluated in 103 isolates.
RESULTS: The chloroquine-resistant haplotypes CVIET and CVMET were identified in 
31.4 and 3.9 % of the isolates, respectively. The frequency of the pfcrt K76T
mutation was increased from 29.3 % in 2013-2014 to 43.2 % in 2014. The pfmdr1
N86Y and Y184F mutations were identified in 6.1 and 53.5 % of the isolates,
respectively. The pfdhfr triple mutant (S108N, N51I and C59R) was detected in the
majority of the isolates (82.3 %). The prevalence of quadruple mutants (pfdhfr
S108N, N51I, C59R and pfdhps A437G) was 40.4 %. One isolate (1.1 %) harboured the
pfdhps mutations A437G and K540E and the pfdhfr mutations S108N, N51I and C59R.
CONCLUSIONS: Despite a decline in the prevalence of chloroquine resistance due to
the official withdrawal of the drug and to the introduction of ACT, the spread of
resistance to chloroquine has continued. Furthermore, susceptibility to
amodiaquine may be decreased as a result of cross-resistance. The frequency of
the pfmdr1 mutation N86Y declined while the Y184F mutation increased in
prevalence, suggesting that selective pressure is acting on pfmdr1, leading to a 
high prevalence of mutations in these isolates and the lack of specific
mutations. The 50.5 % prevalence of the pfmdr1 polymorphisms N86Y and Y184F
suggests a decrease in lumefantrine susceptibility. Based on these results,
intensive surveillance of ACT partner drugs must be conducted regularly in
Senegal.

DOI: 10.1186/s12936-016-1379-2 
PMCID: PMC4937610
PMID: 27387549  [Indexed for MEDLINE]

